News

Phase I Trial of Lupus Oral Inhibitor Meets Safety, Tolerability Targets

Hutchison China MediTech Limited (Chi-Med) recently announced that its R&D subsidiary Hutchison MediPharma (HMP) has completed its Phase I study of HMPL-523, a potential global first-in-class oral inhibitor targeting the spleen tyrosine kinase Syk, a key protein involved in B-cell signaling. Modulation of the B-cell signaling pathway has proven to significantly advance…

Lupus Initiative Using CDC Grant to Educate Patients, Care Providers

The Lupus Initiative (TLI) of The American College of Rheumatology (ACR) was awarded a five-year grant by The Centers for Disease Control and Prevention (CDC). The money will go to supporting development of a national, grassroots program aiming to target individuals with undiagnosed lupus, care providers, and rheumatology healthcare providers. From a diagnostic…

A Call for Better Biomarkers for Systemic Lupus Erythematosus

The promise that the field of biomarkers hold for earlier diagnosis and hence superior treatment of systemic autoimmune diseases were the focus of a recent review in Drug Discovery & Development. Systemic autoimmune diseases like rheumatoid (RA), systemic lupus erythematosus (SLE), Sjögren’s syndrome (SjS), polymyositis/dermatomyositis, and systemic sclerosis (SSc) are disorders…

Lupus Researchers Find Mechanism in Stem Cell Transplants Known to Aid Bones

Transplanted mesenchymal stem cells that can differentiate into several types of cells are known to be beneficial in treating symptoms of lupus disease, though researchers were at a loss as to why. Now, scientists at the University of Pennsylvania, working with collaborators, have shed light on the mechanisms of bone protection provided by this therapy,…

Lupus Foundation of America Gala Honors 2015 Champions in New York City

On Wednesday, October 21, 2015, the Lupus Foundation of America honored several key supporters of the fight against systemic lupus erythematosus (SLE) at the Evening of Hope New York City Gala. The efforts of Alan Siegel, President and Chief Executive Officer, Siegelvision; Fran Tsimoyianis, Executive Assistant, Office of the Chairman, Hudson’s Bay Company;…

Impact of Gender on Lupus to Be Feature of APS Conference

The upcoming and highly anticipated Cardiovascular, Renal and Metabolic Diseases: Physiology and Gender conference, set to take place November 17–20 in Annapolis, Maryland, will be hosted by the American Physiology Society — one of the country’s oldest societies in the field of biomedical sciences, with over 11,000 members and 14 peer-reviewed journals…

Risk of Systemic Lupus Erythematosus Linked To Genetic Variation

Researchers identified that a single nucleotide polymorphism in the sequence of the CD40 gene, a gene with key functions in immune diseases, is associated with susceptibility to systemic lupus erythematosus. The study entitled “The association of CD40 polymorphisms with CD40 serum levels and risk of systemic lupus erythematosus” was…